Please login to the form below

Not currently logged in

Novo Nordisk benefits from strong insulin market

Shares in Novo Nordisk rise and outperform a negative market, as investors identify strong sales figures from sanofi-aventis as a sign that the insulin market is strengthening

Shares in Denmark-headquartered Novo Nordisk have risen and outperformed a negative market, as investors identified strong sales figures from its French competitor sanofi-aventis (S-A) as a sign that the insulin market is strengthening.

Shares in Novo Nordisk were up DKK 4.00 (USD 0.74) or 0.7 per cent to reach DKK 579 (USD 106.4), while the OMXC20 index fell 5.66 points or 1.1 per cent to 494.

Alm Brand analysts have said that Novo Nordisk's share price was boosted as S-A's sales figures strongly suggested that the US insulin market was growing. S-A's Q2 FY07 sales of Lantus (insulin glargine [rDNA origin] injection), a direct competitor with Novo Nordisk's Levemir (insulin detemir [rDNA origin] injection), were up 2.7 per cent higher than expected.

S-A is in the process of reducing the size of its US sales force. Conversely, Novo Nordisk's is expanding its sales personnel, which may help the firm maintain its US market standing, says Alm Brand.

1st August 2007


Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...